Who Paid My Doc
Dawn Dean
Nurse Practitioner, Primary Care Springfield, MO Nurse Practitioner
NPI 1720386659 CMS profile 10725228
440 E Tampa St, Springfield, MO 65806
General payments
$1,685
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Dawn Dean of Springfield, MO is reported in the CMS Open Payments database as having received $1,685 across 90 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 80th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $910 | 42 | |
| 2024 | General | $383 | 20 | |
| 2023 | General | $324 | 24 | |
| 2022 | General | $46 | 3 | |
| 2021 | General | $21 | 1 |
Beside peers
- Dawn Dean
- Nurse Practitioner, Primary Care median
- Middle half of Nurse Practitioner, Primary Care
- National median
In program year 2025, general payments to Dawn Dean were reported at $910. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.
Show as a table
| Year | Dawn Dean | Nurse Practitioner, Primary Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $21 | $137 | $39–$445 | $132 |
| 2022 | $46 | $139 | $44–$421 | $149 |
| 2023 | $324 | $163 | $53–$481 | $160 |
| 2024 | $383 | $176 | $54–$511 | $164 |
| 2025 | $910 | $169 | $51–$499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 134 drugsPart D claims
6,939
Drug cost
$692,708
Branded share of claims
22%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trulicity Dulaglutide | Brand | 118 | $139,936 | |
| Jardiance Empagliflozin | Brand | 45 | $60,517 | |
| Ozempic Semaglutide | Brand | 47 | $48,761 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 45 | $30,488 | |
| Mounjaro Tirzepatide | Brand | 22 | $28,319 | |
| Linzess Linaclotide | Brand | 33 | $24,562 | |
| Spiriva Handihaler Tiotropium Bromide | Brand | 34 | $22,193 | |
| Combivent Respimat Ipratropium/Albuterol Sulfate | Brand | 28 | $20,431 | |
| Rybelsus Semaglutide | Brand | 17 | $20,055 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 11 | $19,926 |
The 10 drugs with the highest cost, of 134 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 14 billing codesPaid by Medicare
$696
Medicare patients
22
Services billed
62
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 68% | |
| Atrial fibrillation | 0% | |
| Cancer | 0% | |
| Alzheimer's or dementia | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 7 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| VRAYLAR |
|
$182 | — | — |
| QULIPTA |
|
$106 | — | — |
| UBRELVY |
|
$27 | — | — |
| Epclusa |
|
$24 | — | — |
| SHINGRIX |
|
$16 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 7 in the dashboard with a free accountRecords
90 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Primary Care in Missouri
Danielle Toal
Nurse Practitioner, Primary Care · Cape Girardeau, MO
Joy Murphy
Nurse Practitioner, Primary Care · Saint Louis, MO
Katrina Selsor
Nurse Practitioner, Primary Care · Sparta, MO
Kelly Esposito
Nurse Practitioner, Primary Care · Saint Louis, MO
Elizabeth Young
Nurse Practitioner, Primary Care · Saint Louis, MO
Carol Harrington
Nurse Practitioner, Primary Care · Independence, MO
Related records
Nurse Practitioner, Primary Care in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Primary Care
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.